329 related articles for article (PubMed ID: 26043110)
1. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
[TBL] [Abstract][Full Text] [Related]
2. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.
Kuo KT; Mao TL; Chen X; Feng Y; Nakayama K; Wang Y; Glas R; Ma MJ; Kurman RJ; Shih IeM; Wang TL
Clin Cancer Res; 2010 Apr; 16(7):1997-2008. PubMed ID: 20233889
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
[TBL] [Abstract][Full Text] [Related]
4. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma.
Yoshimoto T; Matsuura K; Karnan S; Tagawa H; Nakada C; Tanigawa M; Tsukamoto Y; Uchida T; Kashima K; Akizuki S; Takeuchi I; Sato F; Mimata H; Seto M; Moriyama M
J Pathol; 2007 Dec; 213(4):392-401. PubMed ID: 17922474
[TBL] [Abstract][Full Text] [Related]
5. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
[TBL] [Abstract][Full Text] [Related]
6. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
Prat J; D'Angelo E; Espinosa I
Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
[TBL] [Abstract][Full Text] [Related]
8. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
9. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
Veras E; Mao TL; Ayhan A; Ueda S; Lai H; Hayran M; Shih IeM; Kurman RJ
Am J Surg Pathol; 2009 Jun; 33(6):844-53. PubMed ID: 19342944
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
11. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
[TBL] [Abstract][Full Text] [Related]
12. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Wang ZC; Birkbak NJ; Culhane AC; Drapkin R; Fatima A; Tian R; Schwede M; Alsop K; Daniels KE; Piao H; Liu J; Etemadmoghadam D; Miron A; Salvesen HB; Mitchell G; DeFazio A; Quackenbush J; Berkowitz RS; Iglehart JD; Bowtell DD; ; Matulonis UA
Clin Cancer Res; 2012 Oct; 18(20):5806-15. PubMed ID: 22912389
[TBL] [Abstract][Full Text] [Related]
13. Identification of intranuclear inclusions is useful for the cytological diagnosis of ovarian clear cell carcinoma.
Naka M; Ohishi Y; Kaku T; Watanabe S; Tamiya S; Ookubo F; Kato K; Oda Y; Sugishima S
Diagn Cytopathol; 2015 Nov; 43(11):879-84. PubMed ID: 26219930
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Kato N; Sato Y; Kamataki A; Fukase M; Uchigasaki S; Kurose A
Hum Pathol; 2019 Apr; 86():32-37. PubMed ID: 30496799
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma.
Marescalco MS; Capizzi C; Condorelli DF; Barresi V
J Oral Pathol Med; 2014 Jan; 43(1):20-7. PubMed ID: 23750501
[TBL] [Abstract][Full Text] [Related]
16. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
17. BRCA2 alteration is important in clear cell carcinoma of the ovary.
Goodheart MJ; Rose SL; Hattermann-Zogg M; Smith BJ; De Young BR; Buller RE
Clin Genet; 2009 Aug; 76(2):161-7. PubMed ID: 19656163
[TBL] [Abstract][Full Text] [Related]
18. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
Lapke N; Chen CH; Chang TC; Chao A; Lu YJ; Lai CH; Tan KT; Chen HC; Lu HY; Chen SJ
BMC Cancer; 2021 May; 21(1):499. PubMed ID: 33947352
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma.
Lim D; Ip PP; Cheung AN; Kiyokawa T; Oliva E
Am J Surg Pathol; 2015 Aug; 39(8):1061-9. PubMed ID: 25871622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
